205 related articles for article (PubMed ID: 24433361)
1. European Medicines Agency initiatives and perspectives on pharmacogenomics.
Ehmann F; Caneva L; Papaluca M
Br J Clin Pharmacol; 2014 Apr; 77(4):612-7. PubMed ID: 24433361
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenomic information in drug labels: European Medicines Agency perspective.
Ehmann F; Caneva L; Prasad K; Paulmichl M; Maliepaard M; Llerena A; Ingelman-Sundberg M; Papaluca-Amati M
Pharmacogenomics J; 2015 Jun; 15(3):201-10. PubMed ID: 25707393
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Current Regulation and Guidelines of Pharmacogenomic Drug Labels: Opportunities for Improvements.
Shekhani R; Steinacher L; Swen JJ; Ingelman-Sundberg M
Clin Pharmacol Ther; 2020 May; 107(5):1240-1255. PubMed ID: 31715018
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenomics: a new clinical or regulatory paradigm? European experiences of pharmacogenomics in drug regulation and regulatory initiatives.
Prasad K; Breckenridge A
Drug Discov Today; 2011 Oct; 16(19-20):867-72. PubMed ID: 21920454
[TBL] [Abstract][Full Text] [Related]
5. Innovative medicines: new regulatory procedures for the third millennium.
Rasi G; Bonini S
Expert Opin Biol Ther; 2015; 15 Suppl 1():S5-8. PubMed ID: 25777774
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenomics discovery and implementation in genome-wide association studies era.
Ni X; Zhang W; Huang RS
Wiley Interdiscip Rev Syst Biol Med; 2013; 5(1):1-9. PubMed ID: 23188748
[TBL] [Abstract][Full Text] [Related]
7. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
[TBL] [Abstract][Full Text] [Related]
8. [Perspectives on the current state of pharmacogenomics in drug development].
Tamaoki M
Yakugaku Zasshi; 2009 Jan; 129(1):135-45. PubMed ID: 19122441
[TBL] [Abstract][Full Text] [Related]
9. Considerations into pharmacogenomics of COVID-19 pharmacotherapy: Hope, hype and reality.
Al-Taie A; Büyük AŞ; Sardas S
Pulm Pharmacol Ther; 2022 Dec; 77():102172. PubMed ID: 36265833
[TBL] [Abstract][Full Text] [Related]
10. Personalized therapy and pharmacogenomics: future perspective.
Siest G; Marteau JB; Visvikis-Siest S
Pharmacogenomics; 2009 Jun; 10(6):927-30. PubMed ID: 19530959
[No Abstract] [Full Text] [Related]
11. Ubiquitous Pharmacogenomics (U-PGx): The Time for Implementation is Now. An Horizon2020 Program to Drive Pharmacogenomics into Clinical Practice.
Cecchin E; Roncato R; Guchelaar HJ; Toffoli G;
Curr Pharm Biotechnol; 2017; 18(3):204-209. PubMed ID: 28044932
[TBL] [Abstract][Full Text] [Related]
12. Implementing the U.S. FDA guidance on pharmacogenomic data submissions.
Goodsaid F; Frueh FW
Environ Mol Mutagen; 2007 Jun; 48(5):354-8. PubMed ID: 17567848
[TBL] [Abstract][Full Text] [Related]
13. The Ubiquitous Pharmacogenomics consortium: making effective treatment optimization accessible to every European citizen.
Manson LE; van der Wouden CH; Swen JJ; Guchelaar HJ
Pharmacogenomics; 2017 Jul; 18(11):1041-1045. PubMed ID: 28685652
[No Abstract] [Full Text] [Related]
14. DNA, drugs and chariots: on a decade of pharmacogenomics at the US FDA.
Lesko LJ; Zineh I
Pharmacogenomics; 2010 Apr; 11(4):507-12. PubMed ID: 20350131
[TBL] [Abstract][Full Text] [Related]
15. Challenges in implementing yearly enhanced safety surveillance of influenza vaccination in Europe: lessons learned and future perspectives.
Dos Santos G
Hum Vaccin Immunother; 2019; 15(11):2624-2636. PubMed ID: 31116631
[TBL] [Abstract][Full Text] [Related]
16. Applications of pharmacogenomics in regulatory science: a product life cycle review.
Tan-Koi WC; Leow PC; Teo YY
Pharmacogenomics J; 2018 May; 18(3):359-366. PubMed ID: 29205206
[TBL] [Abstract][Full Text] [Related]
17. Global pharmacogenomics: where is the research taking us?
Olivier C; Williams-Jones B
Glob Public Health; 2014; 9(3):312-24. PubMed ID: 24580118
[TBL] [Abstract][Full Text] [Related]
18. Relevance of pharmacogenomics for developing countries in Europe.
Mitropoulos K; Johnson L; Vozikis A; Patrinos GP
Drug Metabol Drug Interact; 2011; 26(4):143-6. PubMed ID: 22017487
[TBL] [Abstract][Full Text] [Related]
19. Progress towards the integration of pharmacogenomics in practice.
Mooney SD
Hum Genet; 2015 May; 134(5):459-65. PubMed ID: 25238897
[TBL] [Abstract][Full Text] [Related]
20. The impact of FDA guidance on pharmacogenomic data submissions on drug development.
Little S
IDrugs; 2005 Aug; 8(8):648-50. PubMed ID: 16044373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
